Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
The global market for Vector-Based RNAi was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Vector-Based RNAi was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Vector-Based RNAi was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Vector-Based RNAi was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Vector-Based RNAi include Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vector-Based RNAi, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Vector-Based RNAi by region & country, by Type, and by Application.
The Vector-Based RNAi market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vector-Based RNAi.
Market Segmentation
By Company
Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals
Segment by Type:
siRNA Design
siRNA Vectors
Custom siRNA Construction
Segment by Application
Hospitals
Speciality Clinics
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Vector-Based RNAi in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Vector-Based RNAi in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Vector-Based RNAi Product Introduction
1.2 Global Vector-Based RNAi Market Size Forecast
1.2.1 Global Vector-Based RNAi Sales Value (2019-2030)
1.2.2 Global Vector-Based RNAi Sales Volume (2019-2030)
1.2.3 Global Vector-Based RNAi Sales Price (2019-2030)
1.3 Vector-Based RNAi Market Trends & Drivers
1.3.1 Vector-Based RNAi Industry Trends
1.3.2 Vector-Based RNAi Market Drivers & Opportunity
1.3.3 Vector-Based RNAi Market Challenges
1.3.4 Vector-Based RNAi Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Vector-Based RNAi Players Revenue Ranking (2023)
2.2 Global Vector-Based RNAi Revenue by Company (2019-2024)
2.3 Global Vector-Based RNAi Players Sales Volume Ranking (2023)
2.4 Global Vector-Based RNAi Sales Volume by Company Players (2019-2024)
2.5 Global Vector-Based RNAi Average Price by Company (2019-2024)
2.6 Key Manufacturers Vector-Based RNAi Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Vector-Based RNAi Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Vector-Based RNAi
2.9 Vector-Based RNAi Market Competitive Analysis
2.9.1 Vector-Based RNAi Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Vector-Based RNAi Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vector-Based RNAi as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 siRNA Design
3.1.2 siRNA Vectors
3.1.3 Custom siRNA Construction
3.2 Global Vector-Based RNAi Sales Value by Type
3.2.1 Global Vector-Based RNAi Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Vector-Based RNAi Sales Value, by Type (2019-2030)
3.2.3 Global Vector-Based RNAi Sales Value, by Type (%) (2019-2030)
3.3 Global Vector-Based RNAi Sales Volume by Type
3.3.1 Global Vector-Based RNAi Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Vector-Based RNAi Sales Volume, by Type (2019-2030)
3.3.3 Global Vector-Based RNAi Sales Volume, by Type (%) (2019-2030)
3.4 Global Vector-Based RNAi Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Speciality Clinics
4.2 Global Vector-Based RNAi Sales Value by Application
4.2.1 Global Vector-Based RNAi Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Vector-Based RNAi Sales Value, by Application (2019-2030)
4.2.3 Global Vector-Based RNAi Sales Value, by Application (%) (2019-2030)
4.3 Global Vector-Based RNAi Sales Volume by Application
4.3.1 Global Vector-Based RNAi Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Vector-Based RNAi Sales Volume, by Application (2019-2030)
4.3.3 Global Vector-Based RNAi Sales Volume, by Application (%) (2019-2030)
4.4 Global Vector-Based RNAi Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Vector-Based RNAi Sales Value by Region
5.1.1 Global Vector-Based RNAi Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Vector-Based RNAi Sales Value by Region (2019-2024)
5.1.3 Global Vector-Based RNAi Sales Value by Region (2025-2030)
5.1.4 Global Vector-Based RNAi Sales Value by Region (%), (2019-2030)
5.2 Global Vector-Based RNAi Sales Volume by Region
5.2.1 Global Vector-Based RNAi Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Vector-Based RNAi Sales Volume by Region (2019-2024)
5.2.3 Global Vector-Based RNAi Sales Volume by Region (2025-2030)
5.2.4 Global Vector-Based RNAi Sales Volume by Region (%), (2019-2030)
5.3 Global Vector-Based RNAi Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Vector-Based RNAi Sales Value, 2019-2030
5.4.2 North America Vector-Based RNAi Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Vector-Based RNAi Sales Value, 2019-2030
5.5.2 Europe Vector-Based RNAi Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Vector-Based RNAi Sales Value, 2019-2030
5.6.2 Asia Pacific Vector-Based RNAi Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Vector-Based RNAi Sales Value, 2019-2030
5.7.2 South America Vector-Based RNAi Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Vector-Based RNAi Sales Value, 2019-2030
5.8.2 Middle East & Africa Vector-Based RNAi Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Vector-Based RNAi Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Vector-Based RNAi Sales Value
6.2.1 Key Countries/Regions Vector-Based RNAi Sales Value, 2019-2030
6.2.2 Key Countries/Regions Vector-Based RNAi Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Vector-Based RNAi Sales Value, 2019-2030
6.3.2 United States Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Vector-Based RNAi Sales Value, 2019-2030
6.4.2 Europe Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Vector-Based RNAi Sales Value, 2019-2030
6.5.2 China Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.5.3 China Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Vector-Based RNAi Sales Value, 2019-2030
6.6.2 Japan Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Vector-Based RNAi Sales Value, 2019-2030
6.7.2 South Korea Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Vector-Based RNAi Sales Value, 2019-2030
6.8.2 Southeast Asia Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Vector-Based RNAi Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Vector-Based RNAi Sales Value, 2019-2030
6.9.2 India Vector-Based RNAi Sales Value by Type (%), 2023 VS 2030
6.9.3 India Vector-Based RNAi Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck & Co.
7.1.1 Merck & Co. Company Information
7.1.2 Merck & Co. Introduction and Business Overview
7.1.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck & Co. Vector-Based RNAi Product Offerings
7.1.5 Merck & Co. Recent Development
7.2 Phio Pharmaceutical
7.2.1 Phio Pharmaceutical Company Information
7.2.2 Phio Pharmaceutical Introduction and Business Overview
7.2.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Phio Pharmaceutical Vector-Based RNAi Product Offerings
7.2.5 Phio Pharmaceutical Recent Development
7.3 Quark Pharmaceuticals
7.3.1 Quark Pharmaceuticals Company Information
7.3.2 Quark Pharmaceuticals Introduction and Business Overview
7.3.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Quark Pharmaceuticals Vector-Based RNAi Product Offerings
7.3.5 Quark Pharmaceuticals Recent Development
7.4 Thermo Fisher Scientific
7.4.1 Thermo Fisher Scientific Company Information
7.4.2 Thermo Fisher Scientific Introduction and Business Overview
7.4.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Thermo Fisher Scientific Vector-Based RNAi Product Offerings
7.4.5 Thermo Fisher Scientific Recent Development
7.5 Silence Therapeutics
7.5.1 Silence Therapeutics Company Information
7.5.2 Silence Therapeutics Introduction and Business Overview
7.5.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Silence Therapeutics Vector-Based RNAi Product Offerings
7.5.5 Silence Therapeutics Recent Development
7.6 Qiagen NV
7.6.1 Qiagen NV Company Information
7.6.2 Qiagen NV Introduction and Business Overview
7.6.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Qiagen NV Vector-Based RNAi Product Offerings
7.6.5 Qiagen NV Recent Development
7.7 Ionis Pharmaceutical
7.7.1 Ionis Pharmaceutical Company Information
7.7.2 Ionis Pharmaceutical Introduction and Business Overview
7.7.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Ionis Pharmaceutical Vector-Based RNAi Product Offerings
7.7.5 Ionis Pharmaceutical Recent Development
7.8 Dicerna Pharmaceuticals
7.8.1 Dicerna Pharmaceuticals Company Information
7.8.2 Dicerna Pharmaceuticals Introduction and Business Overview
7.8.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Offerings
7.8.5 Dicerna Pharmaceuticals Recent Development
7.9 Arrowhead Pharmaceuticals
7.9.1 Arrowhead Pharmaceuticals Company Information
7.9.2 Arrowhead Pharmaceuticals Introduction and Business Overview
7.9.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Offerings
7.9.5 Arrowhead Pharmaceuticals Recent Development
7.10 Arcturus Therapeutics
7.10.1 Arcturus Therapeutics Company Information
7.10.2 Arcturus Therapeutics Introduction and Business Overview
7.10.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Arcturus Therapeutics Vector-Based RNAi Product Offerings
7.10.5 Arcturus Therapeutics Recent Development
7.11 Alnylam Pharmaceuticals
7.11.1 Alnylam Pharmaceuticals Company Information
7.11.2 Alnylam Pharmaceuticals Introduction and Business Overview
7.11.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Offerings
7.11.5 Alnylam Pharmaceuticals Recent Development
8 Industry Chain Analysis
8.1 Vector-Based RNAi Industrial Chain
8.2 Vector-Based RNAi Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Vector-Based RNAi Sales Model
8.5.2 Sales Channel
8.5.3 Vector-Based RNAi Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals
听
听
*If Applicable.